HROW - HARROW, INC.
IEX Last Trade
33.975
0.155 0.456%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:22 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$33.82
0.16
0.46%
Fundamental analysis
13%
Profitability
1%
Dept financing
19%
Liquidity
68%
Performance
10%
Performance
5 Days
-1.14%
1 Month
-19.57%
3 Months
-23.91%
6 Months
56.33%
1 Year
220.06%
2 Year
143.56%
Key data
Stock price
$33.98
DAY RANGE
N/A - N/A
52 WEEK RANGE
$9.43 - $59.23
52 WEEK CHANGE
$208.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Mark L. Baum
Region: US
Website: harrowinc.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: harrowinc.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Harrow Health, Inc. owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases.
Recent news